Serdar Uzar

Dr. Serdar Uzar


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Allergy
Verified
Journal Article
Open access
PDF file
IYIsmail Cem Yilmaz
Ismail Cem Yilmaz
EIEmre Mert Ipekoglu
Emre Mert Ipekoglu
ABArtun Bulbul
Artun Bulbul
NTNilsu Turay
Nilsu Turay
MYMuzaffer Yildirim
Muzaffer Yildirim
MGMayda Gursel
Mayda Gursel
Background: Vaccines that incorporate multiple SARS‐CoV‐2 antigens can further broaden the breadth of virus‐specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS‐CoV‐2 VLP vaccine that incorporates the four structural proteins of SARS‐CoV‐2.Methods: VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography, and characterized by tunable‐resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine.Results: Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS‐CoV‐2. Alum adsorbed, K3‐CpG ODN‐adjuvanted VLPs elicited high titer anti‐S, anti‐RBD, anti‐N IgG, triggered multifunctional Th1‐biased T‐cell responses, reduced virus load, and prevented lung pathology upon live virus challenge in vaccinated animals.Conclusion: These data suggest that VLPs expressing all four structural protein antigens of SARS‐CoV‐2 are immunogenic and can protect animals from developing COVID‐19 infection following vaccination.

1 January 2022 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
SUSerdar Uzar
Serdar Uzar
FSFahriye Sarac
Fahriye Sarac
VGVeli Gulyaz
Veli Gulyaz
HEHakan Enul
Hakan Enul
HYHuseyin Yilmaz
Huseyin Yilmaz
NTNuri Turan
Nuri Turan
Uzar S, et al. Clin Exp Vaccine Res. 2022 Jan;11(1):1-11. https://doi.org/10.7774/cevr.2022.11.1.1

18 November 2021 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
PDF file
EGElif Tugce Aydin Goker
Elif Tugce Aydin Goker
DCDeniz Cagdas
Deniz Cagdas
IBInci Yaman Bajin
Inci Yaman Bajin
MKMusa Gurel Kukul
Musa Gurel Kukul
EAElif Soyak Aytekin
Elif Soyak Aytekin
MKM Tezer Kutluk
M Tezer Kutluk
Click on the article title to read more.

7 June 2020 in Etlik Veteriner Mikrobiyoloji Dergisi
Verified
Journal Article
Closed access
PDF file
VGVeli Gülyaz
Veli Gülyaz
FSFahriye Saraç
Fahriye Saraç
MHMustafa Hasöksüz
Mustafa Hasöksüz
SUSerdar Uzar
Serdar Uzar
En tr Contagious ecthyma (CE) is a zoonotic viral infection and common localized cutaneous infection of young sheep and goats caused by a Parapoxvirus with worldwide distribution. The aim of this study was to use rabbits instead of lambs and kids in immunity and safety studies after production of the CE vaccine. The titres of Pendik CE pathogen strain isolated lamb (E(P)CK4) and attenuated vaccine strain originated lamb (E(P)CK22) used in the study were TCID50 106.50 and 107.00/ml, respectively. In the study to determine the pathogenicity of CE virus (E(P)CK4) in rabbits, it was found that CE virus-specific hyperemia, vesicles and pustules were not observed and did not contain CE virus by PCR test in the scabs in the scarred back-waist regions, and body temperature did not increase in rabbits. In the blood sera of rabbits treated with pathogen CE virus and vaccinated with CE vaccine virus, no antibodies were detected against CE virus. It was found that the vesicles, pustules and scabs appeared on day 3 and the lesions healed on the 15th day. In the immunity study in lambs and kids vaccinated with CE vaccine (E(P)CK22), it was found that CE vaccine virus protects lambs and kids against pathogen CE (E(P)CK4) strain. Contagious Ektima (CE) hastalığı, genç koyun ve oğlaklarda lokalize kutanöz enfeksiyonlara sebebiyet veren, dünyada yaygın olarak bulunan Parapoxvirusların neden olduğu zoonotik viral bir enfeksiyondur. Bu çalışmanın amacı, CE aşısının üretilmesinden sonra bağışıklık ve güvenlik çalışmalarında kuzu ve oğlakların yerine tavşan kullanmaktı. Çalışmada kullanılan kuzulardan izole edilmiş patojen Pendik CE suşu (E(P)CK 4 ) ve attenüe olan (E(P)CK 22 ) aşı suşunun titrelerinin sırasıyla DKID 50 10 6.50 ve 10 7.00 /ml olduğu belirlendi. Tavşanlarda CE virusunun (E(P)CK 4 ) patojenitesini belirleme çalışmasında, CE virusuna özgü hiperemi, veziküller ve püstüller gözlemlenmedi, vücut sıcaklıklarında artış olmadı ve bel bölgesinde bulunan yara kabuklarında CE virusu PCR ile tespit edilmedi. Patojen CE virusu uygulanan ve CE aşı virusu ile aşılanan tavşanların kan serumlarında, CE virusuna karşı antikor tespit edilmedi. CE aşısı (E (P) CK 22 ) ile aşılanmış kuzu ve oğlaklarda yapılan bağışıklık çalışmasında, skarifikasyon yapılan deri bölgesinde veziküllerin, püstüllerin ve kabukların 3. günde ortaya çıktığı ve lezyonların 15. günde iyileştiği tespit edildi. CE aşı virusunun kuzu ve oğlakları patojen CE (E (P) CK 4 ) virusuna karşı koruduğu saptandı.

30 July 2022 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
TATuğba Ayhancı
Tuğba Ayhancı
HTHande Toptan
Hande Toptan
YÖYunus Emre Özer
Yunus Emre Özer
SUSerdar Uzar
Serdar Uzar
HEHakan Enül
Hakan Enül
MAMustafa Altindis
Mustafa Altindis
The coronavirus disease 2019 (COVID-19) turned into a pandemic shortly after emerging in Decem- ber 2019, in the city of Wuhan, China. In this study, it was aimed to investigate the presence of severe acute respiratory system coronavirus-2 (SARS-CoV-2) RNA in various clinical samples and the scattering profile of the virus and the variation of anti-SARS-CoV-2 IgG and neutralizing antibody levels over time in infected patients during and after the period of COVID-19 disease. The study included COVID-19 patients from the community (CCP) (n= 47) (May-June 2020) and healthcare workers (HCWP) (n= 30) (November-December 2020). To investigate the presence of SARS-CoV-2 in clinical samples, oropharynx (OF), nasopharynx (NF), sputum, stool, blood and urine samples were taken from the CCP group on days 0, 3, 7, 14 and 28. For the detection of anti SARS-CoV-2 IgG and neutralizing antibodies serum samples were taken from the CCP group on days 0, 3, 7, 14, 28, 60, 90 and 120 and on days 14, 28, 60, 90, 120 and 150 from HCWP group. Virus RNA was detected by reverse transcription polymerase chain reaction (RT-PCR), anti SARS-CoV-2 IgG antibody levels by enzyme-linked immunosorbent assay (ELISA), neutra- lizing antibody levels (NAb) by cell culture neutralization and representative neutralization test (sVNT) methods. With the onset of the vaccination program in our country, 11 of the HCWP group patients had SARS-CoV-2 vaccine after the second month serum samples were taken, the remaining HCWP group patients did not get vaccinated during the study period. SARS-CoV-2 RNA was detected with the highest rates in NF (100%), stool (65.8%), sputum (45.7%), OF (41.3%), blood (5.3%), and urine (2.2%) samp- les, respectively. It was found that viral shedding continued for 14 days in respiratory tract samples and up to 60 days in stool samples, and no virus was detected in blood samples after the third day. It was observed that the viral load was highest at the time of diagnosis in both upper and lower respiratory tract samples, peaking on the seventh day in stool samples and following an irregular course throughout the disease. Anti-SARS-CoV-2 IgG antibody positivity was found in 41.4% of CCP group patients on the first day of diagnosis, and seroconversion was observed in all patients at the fourth month. During the study period, seropositivity was detected in only 82.1% of the patients in the HCWP group. It was observed that the IgG antibody levels peaked at the 7th day in the CCP group patients and at the third month in the HCWP group patients (S/Co: 9.6 and 2.8, respectively). Anti-SARS-CoV-2 IgG antibody levels detected in the CCP group were found to be significantly higher than the HCWP group (p< 0.05). At the end of the first month, NAb was detected in all (100%) patients in the CCP group. It was found that NAb titers peaked (1/256) on the 28th day and showed a decreasing trend from the second month. NAb median titers were observed to peak earlier in the severe HCWP group (14 days in the severe group, 28 days in the mild group, p> 0.05). It was observed that 6 (26.1%) of HCWP group patients had low, 11 (47.8%) moderate, 6 (26.1%) high titers of representative NAb. The distribution of representative NAb levels by vaccine status was examined and no statistically significant difference was found (p= 0.400, p= 0.077 and p= 0.830, respectively). As a result; SARS-CoV-2 RNA was detected in many samples such as sputum, stool, blood and urine, and it was observed that viral shedding in stool samples could continue for months. Anti-SARS-CoV-2 IgG antibody positivity was observed in most of the patients in the fourth month, and it was found that the antibody titers decreased after the third month. It was determined that protective antibody levels continued in the fourth month. These findings are important in vaccination strategies and in the fight against the pandemic. However, considering the emergence of new mutant forms of the virus in today's conditions where the pandemic continues, more detailed and comprehensi- ve studies are needed for viral shedding and antibody titer studies.

30 December 2021 in Etlik Veteriner Mikrobiyoloji Dergisi
Verified
Journal Article
Closed access
FSFahriye Saraç
Fahriye Saraç
VGVeli Gülyaz
Veli Gülyaz
MHMustafa Hasöksüz
Mustafa Hasöksüz
SUSerdar Uzar
Serdar Uzar
IGİrEm Gülaçti
İrEm Gülaçti
EAEray ATIL
Eray ATIL
Canine adenoviruses (CAV) can infect both domestic and wild canid. Canine Adenovirus Type-1 (CAV-1) and Canine Adenovirus Type-2 (CAV-2) are the cause of infectious canine hepatitis and infectious canine laryngotracheitis, respectively. The epidemiology of the virus is not clear enough in the most territory. For this purpose, data on the virus in Turkey, which is a bridge between continents, were examined. Comparing the sequence data of strains circulated in the field over a ten-year period revealed a genetic heterogeneity. To make this comparision total of 32 fecal samples collected from shelter dogs with diarrhea in 2011 was used. Firstly, virus isolation was performed in MDCK cells and cytopathogenic effects were observed in 4/32 samples. Secondly, the supernatant of four isolates were found positive for the E3 gene of CAV-2 by PCR. Strains were placed on a different branch from other Turkish isolates under the same subgroup in the phylogenetic tree. According to partial E3 gene analysis, seven amino acid substitutions were detected between the strains. Due to Shannon entropy value and ConSurf analysis, all of them were indicated as important antigenic sites. This study pointed out the possible genetic heterogeneity among CAV-2 in Turkey.